NCT06250582 is a NA clinical trial of virtual reality therapy in Dialysis, sponsored by David Blum.

Who is sponsoring NCT06250582?

NCT06250582 is sponsored by David Blum.

What drugs are being tested in NCT06250582?

Interventions in NCT06250582: virtual reality therapy.

What condition does NCT06250582 study?

NCT06250582 studies Dialysis, Virtual Reality.

Is NCT06250582 still recruiting?

NCT06250582 is currently recruiting now. Last updated 27 April 2025.

Last reviewed 2025-04-27 · How we verify

NCT06250582

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Does Virtual Reality Improve Symptom Burden in Dialysis Patients?

Recruiting now NA Last updated 27 April 2025

What this trial tests

NA trial testing virtual reality therapy in Dialysis in 20 participants. Currently enrolling.

Timeline

2 December 2024

Primary endpoint
31 July 2025

31 December 2025

Quick facts

Lead sponsor	David Blum
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	2 December 2024
Primary completion	31 July 2025
Estimated completion	31 December 2025
Sites	1 location across Switzerland

Drugs / interventions tested

virtual reality therapy

Conditions studied

Dialysis — all drugs for Dialysis →
Virtual Reality — all drugs for Virtual Reality →

Sponsor

David Blum

Who can join

18 and older, any sex, with Dialysis or Virtual Reality. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to investigate the use of virtual reality therapy in dialysis patients. The main question it aims to answer is: Does virtual reality improve symptom burden in dialysis patients and improve their mental wellbeing? Over a period of one month, one virtual reality therapy session of 30 minutes will be performed during each regular hemodialysis session. Since we will conduct a monocentric, crossover randomized controlled trial, the participants act as their own control group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Dialysis

Currently open trials in the same condition.

NCT07262320 — Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America · recruiting
NCT07013175 — Wise Choices in the Intensive Care Unit · NA · recruiting
NCT07119593 — Exercise Intensity · NA · recruiting
NCT06933472 — A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China · Phase 3 · recruiting
NCT06905080 — Dialysis Catheter Caps Case Feasibility Study · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06250582 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by David Blum
Last refreshed: 27 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06250582.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing